Renishaw plc
United Kingdom · GB0007323586 · reports in GBP · Europe
Four figures
From the annual report for the year to Jun 30, 2026. Each line says what it is based on.
- Revenue growth
- Revenue +14% in the year to Jun 30, 2026, on the year before.
- Return on equity
- It earned 12% on its shareholders' equity in the year to Jun 30, 2026.
- Equity and assets
- No balance sheet tagged in the filing.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Jun 30, 2026, consolidated, in GBP.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 | |
|---|---|---|---|---|
| Revenue | £689M | £691M | £713M | £816M |
| Operating profit | £134M | £109M | £108M | £135M |
| Net profit to shareholders | £116M | £97M | £84M | £119M |
| Earnings per share | £1.60 | £1.33 | £1.15 | £1.64 |
| Dividend per share | £0.73 | £0.76 | £0.76 | £0.78 |
| Cash from operations | £84M | £124M | £148M | £111M |
| Cash | £81M | £122M | £87M | £148M |
| Equity | £897M | £896M | £926M | £984M |
What they do
In the company's own words, from the annual report.
The principal activities of the Company are the design, manufacture, sale, distribution and service of manufacturing technologies products and services, and analytical instruments and medical devices, as outlined on pages 14 to 20 of the Strategic Report.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.